As part of its All of Us Research Program, the National Institute of Health will issue reports informing study participants if they have increased risks for certain health conditions – and givign them pharmacogenetic information that can indicate how their bodies might pocess certain…
Source: Healthcareitnews.com and Read More
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
